Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635111 · ClinicalTrials.gov registry record
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A clinical trial of Tenosynovial Giant Cell Tumor and Hepatotoxicity, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- 30
- Enrollment target
- 8
- Study locations
NCT04635111 is a study of Tenosynovial Giant Cell Tumor and Hepatotoxicity that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 30 participants, below the 114-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT04635111, a study of Tenosynovial Giant Cell Tumor and Hepatotoxicity, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Conditions Studied
Interventions
- DRUG TURALIO™
Study Locations (8)
California
- Kamalesh K Sankhala MD INC - Santa Monica
- Sarcoma Oncology Research Center LLC - Santa Monica
- UCLA Hematology and Oncology - Santa Monica
- The Oncology Institute of Hope and Innovation - Whittier
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Montefiore Medical Center - New York
Ohio
- OSU - James Comprehensive Cancer Center - Columbus
Texas
- Kelsey Seybold Clinic - Pearland - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2036-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04635111
The ClinicalTrials.gov registry entry for NCT04635111 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (74% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which TURALIO™ is the first listed.
NCT04635111 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04635111 about?
NCT04635111 is a clinical study titled "A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment". A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
What is the current status of trial NCT04635111?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2021-01-07. Estimated completion is 2036-06-01.
What conditions does trial NCT04635111 study?
This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor, Hepatotoxicity.
What interventions are being tested in trial NCT04635111?
The interventions under investigation include: TURALIO™ (DRUG).
Who is sponsoring clinical trial NCT04635111?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04635111 being conducted?
This trial has 8 study locations across California, Massachusetts, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tenosynovial Giant Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
RECRUITING
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
RECRUITING · Phase 1
-
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
-
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.